Bexsero

Meningococcal meningitis survivor and vaccination advocate Leslie Meigs looks on as her brother Andrew (18), a college student in Texas, receives Bexsero®, a meningococcal group B vaccine approved by the FDA for ages 10-25 in January. Meningococcal group B is one of the most prevalent types of meningococcal disease in the US, and adolescents and young adults are at risk due to common lifestyle habits such as living in college dormitories. Bexsero is approved to help protect against the potentially deadly disease in two doses, however is not expected to cover all group B strains.